Skip to main content
. 2021 Mar 18;12:655697. doi: 10.3389/fimmu.2021.655697

Figure 6.

Figure 6

Immunotherapies in ongoing clinical trials for advanced HCC. Several ICIs targeting checkpoints on lymphocytes but also NK and myeloid cells are currently being assessed as monotherapies or in combinations. Additional strategies include CAR-T cells, oncolytic viruses, vaccines, antibody-drug conjugates and bi-specific antibodies.